Quick answer: An estimated 25% of the population carries HLA-DR immune response gene variants (HLA-DR 4-3-53, 11-3-52B, and others) that impair the ability to generate antibodies against biotoxins — meaning that when these individuals are exposed to mold, cyanobacteria, dinoflagellates, or Lyme disease, the biotoxins remain in circulation indefinitely, triggering a multi-system inflammatory cascade called Chronic Inflammatory Response Syndrome (CIRS). Shoemaker 2018 estimated that CIRS affects approximately 24 million Americans, making it the most common cause of chronic multi-system illness that mainstream medicine consistently misdiagnoses as fibromyalgia, chronic fatigue, depression, or anxiety.
What Is CIRS? The Shoemaker Protocol and Biotoxin Illness Framework
Chronic Inflammatory Response Syndrome (CIRS) is a multi-system, multi-symptom illness driven by persistent biotoxin exposure in genetically susceptible individuals. The framework was developed by Ritchie Shoemaker, MD — a rural Maryland physician who identified a cluster of patients with unexplained multi-system illness after exposure to a cyanobacteria bloom in Chesapeake Bay in the 1990s — and subsequently validated through extensive peer-reviewed research including over 160 published papers and two completed NIH studies.
The central mechanism of CIRS: biotoxins (trichothecene mycotoxins from Stachybotrys, gliotoxin from Aspergillus, microcystin from cyanobacteria, neurotoxins from Pfiesteria, or Borrelia biotoxins from tick-borne illness) bind to receptors on peripheral nerve cells and innate immune pattern recognition receptors. In individuals with functional HLA-DR response genes, these biotoxins are quickly processed and eliminated. In HLA-DR susceptible individuals, biotoxins are not efficiently processed by antigen-presenting cells, remain in circulation, and continuously re-bind receptors — triggering a self-perpetuating innate immune inflammatory response that continues even after the biotoxin source is removed.
The downstream effects of this persistent innate immune activation follow a predictable sequence that Shoemaker has mapped through extensive biomarker research: Step 1 — TGF-beta-1 elevation (pro-fibrotic cytokine) → Step 2 — MMP-9 elevation (metalloproteinase, causing tissue remodeling and BBB disruption) → Step 3 — VEGF dysregulation (vascular endothelial growth factor — causing capillary dropout and poor oxygen delivery to tissues) → Step 4 — ADH/osmolality dysregulation (producing the characteristic excessive thirst and frequent urination or ice-cold despite warm temperatures) → Step 5 — MSH depletion (alpha-melanocyte-stimulating hormone — the master regulatory peptide governing melatonin, cortisol, ACTH, gut permeability, testosterone, and pain sensitivity) → Step 6 — Leptin resistance and weight gain (hypothalamic leptin resistance driven by MSH depletion) → Step 7 — ACTH/cortisol dysregulation (adrenal insufficiency pattern) → Step 8 — ADH/hyperosmolality in some patients → Step 9 — MARCoNS (multiple antibiotic resistant coagulase-negative Staphylococci) colonization of nasal sinuses (which produce exotoxins that further deplete MSH, creating a positive feedback loop perpetuating CIRS).
Mold Toxins: Trichothecenes, Ochratoxin, Aflatoxin, and Gliotoxin
Water-damaged buildings are the primary source of biotoxin exposure in CIRS. A 2009 EPA review estimated that approximately 45% of buildings in the United States have significant water damage, and the WHO Global Burden of Disease 2009 report concluded that 30% of new or remodeled buildings had excess moisture. The relevant molds produce multiple classes of mycotoxins with distinct biological effects:
Trichothecene mycotoxins (produced by Stachybotrys chartarum — “black mold” — and Fusarium species) are among the most potent biological toxins known. They inhibit protein synthesis by disrupting ribosomal function at the peptidyl transferase step — the same mechanism as the ricin toxin, but at lower concentration. Trichothecenes are both cytotoxic and immunosuppressive: they reduce natural killer cell activity, suppress T cell proliferation, and impair the IgA secretory immune response, increasing susceptibility to upper respiratory infections. Because they are fat-soluble, they accumulate in cell membranes and are not easily excreted — making activated charcoal and cholestyramine binding agents essential for elimination.
Ochratoxin A (produced by Aspergillus and Penicillium — the most common indoor molds) is nephrotoxic, immunotoxic, and carcinogenic (IARC Group 2B). It inhibits phenylalanine metabolism, impairs protein synthesis, and generates reactive oxygen species in renal tubular cells — a mechanism for the kidney damage seen in ochratoxicosis. It suppresses specific IgA production (one of the primary mucosal immune defenses) and is commonly detected in the urine of patients with CIRS using MycoTOX urine mycotoxin testing. Aflatoxin B1 (Aspergillus flavus/parasiticus) is the most potent known naturally occurring carcinogen — primarily affecting the liver through cytochrome P450 epoxidation to the highly reactive aflatoxin B1-8,9-epoxide, which forms DNA adducts with guanine. Gliotoxin (Aspergillus fumigatus) suppresses T cell and macrophage function through different mechanisms — it inhibits phagocytosis, induces apoptosis in lymphocytes, and impairs the oxidative burst of neutrophils, effectively paralyzing innate immune response in the lung. Combined with Aspergillus tissue invasion, it creates serious fungal infections in immunocompromised individuals and subtler immune dysfunction in CIRS patients.
Diagnosing CIRS: The Shoemaker Biomarker Panel
CIRS diagnosis is supported by a specific pattern of abnormal biomarkers — the “fingerprint” of the biotoxin illness pathway. No single test is pathognomonic, but the combination of HLA-DR susceptibility testing, characteristic biomarker pattern, and clinical symptom cluster (using the standardized 37-symptom cluster questionnaire) provides a clinically robust diagnosis. Key biomarkers include:
TGF-beta-1: Should be <2,380 pg/mL (LabCorp); elevated in 80%+ of active CIRS cases. MMP-9: Normal <332 ng/mL; elevated in CIRS, correlates with cognitive and inflammatory symptoms. VEGF: May be low (<31 pg/mL) or elevated depending on stage — low VEGF reflects capillary dropout and explains exercise intolerance and muscle pain. C4a: The most sensitive CIRS biomarker — elevated >2,830 ng/mL; C4a is a split complement protein that cannot be eliminated by the spleen, accumulating when the alternative complement pathway is chronically activated. MSH (alpha-MSH): Should be 35–81 pg/mL; depleted below 35 in 96% of CIRS patients with MARCoNS. MSH depletion explains the pain sensitivity, sleep disruption, fatigue, and hormonal cascade of advanced CIRS. ADH and serum osmolality: ADH may be low or discordant with osmolality — producing the characteristic CIRS thirst pattern and frequent urination. VIP (vasoactive intestinal polypeptide): Low VIP (<23 pg/mL) is the final biomarker depleted in the Shoemaker pathway — correlating with pulmonary symptoms, exercise intolerance, and cognitive dysfunction. VIP nasal spray is used in the final step of CIRS treatment. ACTH and cortisol: Discordant pattern (low ACTH with low-normal cortisol) represents central adrenal suppression from MSH depletion. HLA-DR typing: Identifies susceptible haplotypes — confirms genetic predisposition but does not establish current CIRS activity.
Visual Contrast Sensitivity (VCS) testing — the ability to distinguish contrast at low light levels — is impaired in CIRS through neurotoxin effects on parvocellular visual processing pathways. The standardized VCS test (Shoemaker/Berndtson protocol at survivingmold.com) has 87% sensitivity and 77% specificity for CIRS as a free screening tool. Negative VCS makes CIRS less likely; positive VCS plus symptom cluster warrants full biomarker testing. ERMI (Environmental Relative Moldiness Index) and HERTSMI-2 (Health Effects Roster of Type-Specific Formers of Mycotoxins and Inflammagens, score out of 25 that predicts CIRS-risk buildings) are the most validated building assessment tools — using settled dust DNA analysis to quantify pathogenic mold species burden.
The 11-Step Shoemaker Protocol for CIRS Treatment
CIRS treatment follows a strict sequential protocol — each step must be addressed in order, as treating later steps without earlier ones is ineffective or counterproductive. The foundational requirement is removal from the biotoxin source: no treatment will succeed if the patient continues to live or work in a water-damaged building. ERMI/HERTSMI-2 assessment is required before initiating treatment.
Step 1 — Remove from exposure: Leave the water-damaged building. Personal belongings (especially porous items: books, cardboard boxes, furniture, soft goods) may harbor mycotoxins and require remediation or disposal. ERMI score <2 or HERTSMI-2 <11 is the required building safety threshold. Step 2 — Binding agents: Cholestyramine (prescription anion exchange resin, 4g before meals 4×/day — binds mycotoxins, bile acid-transported biotoxins, and Lyme neurotoxins for fecal elimination) or Welchol (colesevelam, for patients who cannot tolerate cholestyramine) or naturopathic alternatives (activated charcoal, GI Detox, or saccharomyces cerevisiae — less evidence for severe CIRS but appropriate for milder cases). Shoemaker’s RCT (Acta Tropica 2002) demonstrated CSM produced 70% symptom reduction. Step 3 — MARCoNS eradication: If deep nasal culture confirms MARCoNS, BEG spray (bacitracin, EDTA, gentamicin) is applied twice daily for 1–2 months. MARCoNS eradication is prerequisite to MSH recovery. Step 4 — Correct food sensitivities: Amylose-free diet (eliminating high-amylose starches like white rice and potatoes that elevate TGF-beta-1 through lectin-like activity — not the same as the typical “leaky gut” elimination diet). Steps 5–11: Correct androgens/ADH imbalance; correct VIP; address MMP-9, VEGF, C4a, TGF-beta-1 in sequence using targeted interventions; VIP nasal spray (prescribed by CIRS-literate physicians under FDA-IND or compounding pharmacy protocols) in the final step — which corrects the residual pulmonary and cognitive symptoms that do not resolve with earlier steps.
Functional Detoxification Support in CIRS
Beyond the Shoemaker protocol, functional medicine addresses the broader detoxification and mitochondrial dysfunction in CIRS. Glutathione depletion is universal in mycotoxin illness — trichothecenes and gliotoxin both deplete glutathione directly through conjugation. IV glutathione (600–1,200 mg twice weekly), N-acetylcysteine 1,800 mg/day (glutathione precursor), and liposomal glutathione 500 mg/day provide critical antioxidant support. Sulforaphane at 30–60 mg/day activates NRF2, upregulating the entire Phase 2 detoxification enzyme system (glutathione-S-transferases, NQO1, HO-1) — multiplying intracellular glutathione production rather than simply replacing it. Mitochondrial support: Mycotoxins directly impair Complex I and Complex II of the electron transport chain — CoQ10 ubiquinol 300–400 mg, NAD+ precursors (NMN/NR), and acetyl-L-carnitine address the energy production deficit. Binders beyond CSM: Bentonite clay, activated charcoal, zeolite, and modified citrus pectin bind different mycotoxin classes and heavy metals that co-accumulate in water-damaged environments. Lipid replacement therapy: Fat-soluble mycotoxins accumulate in cell membranes — phosphatidylcholine liposomal forms help replace toxin-laden membrane phospholipids. Sauna therapy (Laukkanen 2018 — Finnish sauna study: 50% cardiovascular mortality reduction with 4+/week use) enhances dermal mycotoxin excretion while supporting detoxification through heat-shock protein activation.
Frequently Asked Questions
How do I know if I have mold illness (CIRS)?
CIRS presents with a characteristic multi-system symptom cluster: fatigue, weakness, cognitive impairment (memory, concentration, word-finding), unusual shortness of breath, static shocks, excessive thirst and urination, sensitivity to light/sound, mood changes, joint pain, morning stiffness, and temperature dysregulation. The free VCS (visual contrast sensitivity) test at survivingmold.com provides an initial screen — positive result plus residence or work in a water-damaged building warrants full CIRS biomarker testing (TGF-beta-1, C4a, MMP-9, MSH, VEGF, VIP) and HLA-DR typing.
Does leaving a moldy building cure mold illness?
Leaving the building is necessary but not sufficient. In HLA-DR susceptible individuals, biotoxins recirculate through enterohepatic circulation rather than being eliminated — meaning the inflammatory cascade continues even after exposure ends. Binding agents (cholestyramine or alternatives) are required to interrupt this recirculation and excrete accumulated biotoxins. The characteristic recirculation mechanism is why CIRS patients deteriorate again if re-exposed to even trace mold — their innate immune systems are primed and re-activate rapidly.
What is the difference between mold allergy and mold toxicity?
Mold allergy is an IgE-mediated adaptive immune response to mold spore proteins — producing the typical rhinitis, asthma, and skin reactions treated by allergists. Mold toxicity (CIRS) is an innate immune response to mycotoxins — small, non-protein molecules that are not detected by allergy testing and require entirely different evaluation (urine mycotoxin testing, CIRS biomarker panel). A patient can be allergy-skin-test negative but have severe mycotoxin illness. Standard IgE allergy testing will not detect mycotoxin-driven CIRS.
What diet helps with CIRS and mold illness?
The Shoemaker protocol specifies an amylose-free diet — eliminating high-amylose starches (white potatoes, white rice, corn, high-amylose wheat) that elevate TGF-beta-1 through a lectin-like receptor mechanism. Beyond this, a low-mycotoxin diet eliminates foods with high mycotoxin contamination risk: peanuts and peanut butter (Aspergillus contamination), corn, wheat, alcohol (fermentation produces mycotoxins), coffee, dried fruits, and aged cheeses. Emphasizing organic produce, grass-fed meats, and wild-caught fish reduces mycotoxin dietary load while providing the anti-inflammatory nutrients needed for CIRS recovery.
Mold illness and CIRS represent one of the most underdiagnosed sources of chronic multi-system illness in medicine today. At The Private Practice, we offer comprehensive CIRS evaluation including the full Shoemaker biomarker panel, HLA-DR typing, urine mycotoxin testing, and a stepwise evidence-based treatment protocol. Call us at (810) 206-1402 to schedule your CIRS evaluation.